Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients
NCT07290894Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2026
- Primary completion
- Oct 2031
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, lenvatinib in vulvar cancer, sponsored by National Cancer Institute. Started Mar 2026; status: recruiting.
02
Drugs
pembrolizumablenvatinib
03
Conditions
vulvar cancer
Beyond the preview
Go deeper on NCT07290894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07290894.